TY - JOUR
T1 - Management and treatment of glomerular diseases (part 2)
T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
AU - Conference Participants
AU - Rovin, Brad H.
AU - Caster, Dawn J.
AU - Cattran, Daniel C.
AU - Gibson, Keisha L.
AU - Hogan, Jonathan J.
AU - Moeller, Marcus J.
AU - Roccatello, Dario
AU - Cheung, Michael
AU - Wheeler, David C.
AU - Winkelmayer, Wolfgang C.
AU - Floege, Jürgen
AU - Adler, Sharon G.
AU - Alpers, Charles E.
AU - Ayoub, Isabelle
AU - Bagga, Arvind
AU - Barbour, Sean J.
AU - Barratt, Jonathan
AU - Chan, Daniel T.M.
AU - Chang, Anthony
AU - Choo, Jason Chon Jun
AU - Cook, H. Terence
AU - Coppo, Rosanna
AU - Fervenza, Fernando C.
AU - Fogo, Agnes B.
AU - Fox, Jonathan G.
AU - Glassock, Richard J.
AU - Harris, David
AU - Hodson, Elisabeth M.
AU - Hoxha, Elion
AU - Iseki, Kunitoshi
AU - Jennette, J. Charles
AU - Jha, Vivekanand
AU - Johnson, David W.
AU - Kaname, Shinya
AU - Katafuchi, Ritsuko
AU - Kitching, A. Richard
AU - Lafayette, Richard A.
AU - Li, Philip K.T.
AU - Liew, Adrian
AU - Lv, Jicheng
AU - Malvar, Ana
AU - Maruyama, Shoichi
AU - Mejía-Vilet, Juan Manuel
AU - Mok, Chi Chiu
AU - Nachman, Patrick H.
AU - Nester, Carla M.
AU - Noiri, Eisei
AU - O'Shaughnessy, Michelle M.
AU - Özen, Seza
AU - Parikh, Samir M.
N1 - Funding Information:
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Achillion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCentryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma.
Funding Information:
BHR declared having received consultancy fees from Alexion, Aurinia, Biogen, Biomarin, Bristol-Myers Squibb, ChemoCentryx, EMD Serono, Frazier Life Sciences, Genentech, Gilead, Lupus Foundation of America, Mallinckrodt, MedImmune, Novartis, Pharmalink, Ra Pharmaceuticals, Retrophin, and Rigel; and travel support from American Society of Nephrology, Aurinia, Biogen, Budapest Nephrology School, Childhood Arthritis and Rheumatology Research Alliance, Chemocentryx, Congress on SLE (Australia), Central Society for Clinical and Translational Research-Midwestern American Federation for Medical Research, CureGN, European League Against Rheumatism Congress and Portuguese Congress, KDIGO, MENTOR (Multicenter Randomized Controlled Trial of Rituximab), Office of Minority Health Impact for Lupus, Pharmalink, Ra Pharmaceuticals, Retrophin, and UpToDate. DJC declared having received research support from National Institutes of Health. DCC declared having received consultancy fees from Alnylam, Calliditas, ChemoCentryx, Dimerix, Mallinckrodt, Novartis, and Rigel; and research support from Genentech and National Institute of Diabetes, Digestive, and Kidney Diseases. KLG declared having served on the chronic kidney disease advisory board of Reata. JJH declared having received consultancy fees from Aurinia, Dimerix, and Variant. MJM declared having received research support from German Ministry for Science and Education (BMBF) and German Research Foundation (DFG). DCW declared having received consultancy fees from Akebia, AstraZeneca, Amgen, Boehringer Ingelheim, GlaxoSmithKline, Janssen, and Vifor Fresenius; speaker honoraria from Amgen and Vifor Fresenius; and research support from AstraZeneca. WCW declared having received consultancy fees from Akebia, AMAG, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from National Institutes of Health. JF declared having received consultancy fees from Amgen, Alnylam, Bayer, Boehringer Ingelheim, Calliditas, Inositec, Novo Nordisk, Omeros, and Vifor; speaker honoraria from Amgen and Vifor; and travel support from Boehringer Ingelheim. All other authors declared no competing interests.
Publisher Copyright:
© 2019 The Author(s)
PY - 2019/2
Y1 - 2019/2
N2 - In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody–associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.
AB - In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody–associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.
KW - C3 glomerulopathy
KW - KDIGO
KW - anti-neutrophil cytoplasmic antibody–associated vasculitis
KW - focal and segmental glomerulosclerosis
KW - lupus nephritis
KW - membranoproliferative glomerulonephritis
KW - minimal change disease
KW - monoclonal gammopathies of renal significance
UR - http://www.scopus.com/inward/record.url?scp=85059847897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059847897&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2018.11.008
DO - 10.1016/j.kint.2018.11.008
M3 - Article
C2 - 30665569
AN - SCOPUS:85059847897
SN - 0085-2538
VL - 95
SP - 281
EP - 295
JO - Kidney International
JF - Kidney International
IS - 2
ER -